LISTED cannabis and dermatology company Botanix has provided its investors with a status update presentation via the ASX.
The company reinforced its dermatology focus and reminded investors of its FDA approval for Epidiolex (PD 27 Jun) and the impending success of its novel skin delivery technology Permatrex which enhances dermal delivery of cannabidiol - asx.com.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Nov 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Nov 18
